2026-05-17T03:17:46Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/116202026-05-15T06:32:10Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

2026-05-14T07:56:16Z urn:hdl:10259/11620 An Overview of Endometriosis and Potential Pharmacogenetic Targets Pérez Gómez, Noelia Martínez-Zamora, María Ángeles Carmona, Francisco Novalbos, Jesús Abad-Santos, Francisco Koller, Dora Saiz Rodríguez, Miriam Drug response Endometriosis Pharmacogenetics Precision medicine Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10–15% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis. Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies. Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care. 2026-05-14T07:56:16Z 2026-05-14T07:56:16Z 2026-03 info:eu-repo/semantics/article 0724-8741 https://hdl.handle.net/10259/11620 10.1007/s11095-026-04049-9 1573-904X eng Pharmaceutical Research. 2026, V. 43, n. 3, p. 605-618 https://doi.org/10.1007/s11095-026-04049-9 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional Springer